Angiotech Pharmaceuticals, a Vancouver, Canada-based medical device company focused on high value medical consumables in the wound closure and ophthalmology sectors, closed a financing round of undisclosed amount.
The terms of the transaction were not disclosed.
The round was led by Vivo Capital and ZQ Capital with participation from GSO Capital Partners, China Orient Asset Management (International) Holding Limited, Fung Shing Investments, ZZ Capital Co., ABCI Investment Management Limited, Cathay Venture and Nan Fung Group.
Led by John R. Barr, Chief Executive Officer, Angiotech is a diversified medical device manufacturer of branded, private label and OEM products with partnerships within dental, ophthalmic, plastic surgery, dermatology, orthopedics, urology, microsurgery, veterinary and trauma specialties. The company has more than 2,000 employees worldwide, has manufacturing facilities in England, Puerto Rico, Mexico and Germany, and sells to customers in over 80 countries.